Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report
- PMID: 39219779
- PMCID: PMC11364487
- DOI: 10.1002/ccr3.9305
Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report
Abstract
Key clinical message: This case study describes the feasibility and safety of psychedelic-assisted therapy (PAT) as a home-based intervention for a patient with throat cancer experiencing significant existential distress. The patient tolerated the intervention well. This case supports the feasibility and safety of PAT for patients with life-threatening conditions in a home setting.
Abstract: Psychedelic-assisted therapy (PAT), as it is practiced today, merges traditional psychotherapeutic techniques with the use of psychedelics such as LSD, psilocybin, or MDMA with the aim of unlocking deeper insights in patients and treating mental conditions that are resistant to other forms of therapy. The present case study describes the safety of PAT as a home-based intervention for a patient with throat cancer experiencing significant existential distress. The patient tolerated the intervention well and was asked to report on measures of anxiety, depression, and distress related to his somatic condition. The observations provided by this clinical case report align with previous findings, suggesting that PAT can be safely applied to potentially provide relief from existential distress in patients with life-threatening conditions. As this is a single-case study, generalizations should be made cautiously. Moreover, placebo effects, expectancy effects, and the natural course of the disease may influence outcomes. Future research should consider controlled trials to ascertain the efficacy and safety of such interventions in diverse settings.
Keywords: home treatment; palliative care; psychedelic; psychedelic‐assisted therapy; throat cancer.
© 2024 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. By declaring no competing interests, the authors affirm that their research findings and interpretations are presented without any undue influence from personal or financial relationships.
Similar articles
-
Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies.BMC Palliat Care. 2021 Dec 20;20(1):191. doi: 10.1186/s12904-021-00889-x. BMC Palliat Care. 2021. PMID: 34930220 Free PMC article.
-
Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.Ann Palliat Med. 2024 Nov;13(6):1490-1501. doi: 10.21037/apm-24-35. Epub 2024 Aug 16. Ann Palliat Med. 2024. PMID: 39168642 Review.
-
Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science.Transl Behav Med. 2024 Nov 25;14(12):744-752. doi: 10.1093/tbm/ibae053. Transl Behav Med. 2024. PMID: 39419768
-
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.Psychopharmacology (Berl). 2022 Jan;239(1):15-33. doi: 10.1007/s00213-021-06027-y. Epub 2021 Nov 23. Psychopharmacology (Berl). 2022. PMID: 34812901 Review.
-
Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care.Neuropharmacology. 2022 Sep 15;216:109174. doi: 10.1016/j.neuropharm.2022.109174. Epub 2022 Jun 27. Neuropharmacology. 2022. PMID: 35772523 Review.
References
-
- Nutt D, Castle D. Psychedelics as Psychiatric Medications. 1st ed. Oxford University Press; 2023. doi:10.1093/med/9780192863607.001.0001 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Research Materials